Atria Investments Inc trimmed its position in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 27.3% during the fourth quarter, Holdings Channel reports. The firm owned 64,518 shares of the company’s stock after selling 24,176 shares during the quarter. Atria Investments Inc’s holdings in Zoetis were worth $8,118,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently bought and sold shares of the business. CIBC Asset Management Inc lifted its holdings in Zoetis by 4.3% during the 3rd quarter. CIBC Asset Management Inc now owns 251,495 shares of the company’s stock worth $36,745,000 after buying an additional 10,434 shares in the last quarter. Nordea Investment Management AB grew its stake in shares of Zoetis by 79.2% in the fourth quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock worth $622,222,000 after acquiring an additional 2,179,578 shares in the last quarter. Seilern Investment Management Ltd grew its stake in shares of Zoetis by 361.2% in the fourth quarter. Seilern Investment Management Ltd now owns 333,465 shares of the company’s stock worth $41,957,000 after acquiring an additional 261,155 shares in the last quarter. Assenagon Asset Management S.A. increased its position in shares of Zoetis by 134.4% during the fourth quarter. Assenagon Asset Management S.A. now owns 1,631,619 shares of the company’s stock worth $205,290,000 after acquiring an additional 935,432 shares during the period. Finally, Mitsubishi UFJ Trust & Banking Corp boosted its stake in shares of Zoetis by 6.5% in the 3rd quarter. Mitsubishi UFJ Trust & Banking Corp now owns 295,482 shares of the company’s stock valued at $43,235,000 after buying an additional 18,040 shares during the period. 92.80% of the stock is currently owned by hedge funds and other institutional investors.
Zoetis Trading Down 1.8%
NYSE ZTS opened at $74.11 on Friday. The firm’s fifty day moving average is $112.28 and its two-hundred day moving average is $120.94. Zoetis Inc. has a one year low of $72.38 and a one year high of $172.23. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. The firm has a market cap of $31.07 billion, a PE ratio of 12.29, a P/E/G ratio of 1.23 and a beta of 0.87.
Analyst Upgrades and Downgrades
A number of research firms recently weighed in on ZTS. Weiss Ratings lowered shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, March 27th. Piper Sandler reiterated a “neutral” rating and set a $135.00 price target (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. Wall Street Zen downgraded shares of Zoetis from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Morgan Stanley restated an “overweight” rating and issued a $115.00 price objective on shares of Zoetis in a report on Friday. Finally, Leerink Partners reiterated a “market perform” rating on shares of Zoetis in a research note on Tuesday, March 10th. Seven analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $137.50.
Get Our Latest Stock Report on Zoetis
Insiders Place Their Bets
In other news, Director Frank A. Damelio purchased 6,650 shares of the company’s stock in a transaction dated Wednesday, May 13th. The shares were acquired at an average cost of $75.39 per share, for a total transaction of $501,343.50. Following the completion of the purchase, the director directly owned 21,458 shares in the company, valued at $1,617,718.62. The trade was a 44.91% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Michael B. Mccallister purchased 3,000 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The shares were purchased at an average cost of $77.76 per share, with a total value of $233,280.00. Following the completion of the acquisition, the director directly owned 24,524 shares of the company’s stock, valued at $1,906,986.24. This represents a 13.94% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders bought 11,650 shares of company stock worth $886,384. 0.22% of the stock is owned by insiders.
Zoetis Company Profile
Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.
Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.
Read More
- Five stocks we like better than Zoetis
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
